《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》解读(七):抗肿瘤药物相关肾损伤的管理  

Interpretation of Clinical Practice Guidelines for Management of Kidney Injury during Anticancer Drug Therapy 2022(Ⅶ):management of anticancer drug-induced kidney injury

作　　者：宋岩[1] 徐菱忆 赵思邈 郑茜子[2] 杨莉[2] Song Yan;Xu Lingyi;Zhao Simiao;Zheng Xizi;Yang Li(Department of Nephrology,First Medical Center,Chinese PLA General Hospital,Beijing 100853,China;Renal Division,Peking University First Hospital,Institute of Nephrology,Peking University,Key Laboratory of Renal Disease,Ministry of Health of China,Key Laboratory of CKD Prevention and Treatment,Ministry of Education of China,Research Units of Diagnosis and Treatment of Immune‑Mediated Kidney Diseases,Chinese Academy of Medical Sciences,Beijing 100034,China;Department of Pharmacy,Peking University First Hospital,Beijing 100034,China)

机构地区：[1]解放军总医院第一医学中心肾脏病学部肾脏病科,北京100853 [2]北京大学第一医院肾内科,北京大学肾脏病研究所,卫生部肾脏疾病重点实验室,慢性肾脏病防治教育部重点实验室(北京大学),中国医学科学院免疫介导肾病诊治创新单元,北京100034 [3]北京大学第一医院药剂科,北京100034

出　　处：《药物不良反应杂志》2024年第11期641-646,共6页Adverse Drug Reactions Journal

基　　金：国家自然科学基金(82300764);北京市科技新星计划(2021051);中央高校基本科研业务费,北京大学临床科学家计划(BMU2023PYJH023);首都卫生发展科研专项(首发2022⁃1⁃4071)。

摘　　要：抗肿瘤药物是肿瘤患者发生肾损伤的重要原因之一,肾损伤一旦发生将影响抗肿瘤治疗及患者预后。因此,日本肾脏病学会、日本临床肿瘤学会、日本医学肿瘤学会和日本肾脏病药物治疗学会共同制订的《抗肿瘤药物治疗期间肾损伤管理临床实践指南(2022)》中对抗肿瘤药物肾损伤的预防与管理进行了具体的论述。本文将重点从细胞毒性抗肿瘤药物、靶向抗肿瘤药物和免疫检查点抑制剂相关肾损伤的管理进行解读,以期更有效地指导临床实践。Anticancer drugs are important causes of kidney injury in cancer patients.Once kidney injury occurs,it will affect anticancer therapy and patient prognosis.Thus,the Japanese Society of Nephrology,Japan Society of Clinical Oncology,Japanese Society of Medical Oncology,and Japanese Society of Nephrology and Pharmacotherapy have jointly formulated the Clinical Practice Guidelines for Management of Kidney Injury During Anticancer Drug Therapy 2022 and made a particular discussion on the prevention and management of anticancer drug-induced kidney injury.This article focuses on interpreting the manage-ment of kidney injury related to cytotoxic anticancer drugs,targeted therapies,and immune checkpoint inhibitors to more effectively guide clinical practice.

关 键 词：抗肿瘤药物 急性肾损伤 肾脏疾病 指南 

分 类 号：R979.1[医药卫生—药品]